Today, the Sr. VP & Chief Scientific Off. of Innoviva Inc (NASDAQ: INVA), Theodore Witek, sold shares of INVA for $163.6K.
See today’s analyst top recommended stocks >>
Based on Innoviva Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $70.54 million and quarterly net profit of $54.63 million. In comparison, last year the company earned revenue of $62.02 million and had a net profit of $35.15 million. INVA’s market cap is $1.43B and the company has a P/E ratio of 9.80. Currently, Innoviva Inc has an average volume of 963.2K.
Four different firms, including Merrill Lynch and Morgan Stanley, currently also have a Sell rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.
